Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.01/15/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news